+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin



Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin



American Journal of Respiratory and Critical Care Medicine 151(2 Pt 1): 384-389



To investigate the capacity of the pulmonary vascular bed to acutely vasodilate, we examined in 35 consecutive patients with primary pulmonary hypertension (PPH), the hemodynamic effects of incremental inhalation periods of an air-NO mixture at different concentrations (10, 20, and 40 ppm), and compared them with those of an acute infusion of prostacyclin (PGI2). An individual pulmonary vasodilator response was defined by a fall in total pulmonary resistance (TPR) > or = 30% relative to mean TPR baseline value. Thirteen patients were responders and 22 were nonresponders to both drugs, and they did not significantly differ in overall baseline characteristics except for mean right atrial pressure (p < 0.03). In responders, both drugs produced similar individual vasodilator response. Changes in mean pulmonary arterial pressure and TPR observed during NO and PGI2 were closely correlated (r2 = 0.9, p < 0.001, and r2 = 0.7, p < 0.01, respectively). The vasodilator response to NO was not concentration-related with a maximal effect obtained at 10 ppm. Combination of both drugs did not lead to any additive vasodilator response. Unlike PGI2, NO did not induce any systemic effect, no adverse reaction, but a moderate increase in methemoglobin. Inhaled NO at low dose (10 ppm) appears to be an effective, safe, and reliable substitute for PGI2 in screening for acute pulmonary vasodilator responsiveness during therapeutic assessment of patients with PPH.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008874085

Download citation: RISBibTeXText

PMID: 7842196

DOI: 10.1164/ajrccm.151.2.7842196


Related references

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Inhaled nitric oxide vs prostacyclin in primary pulmonary hypertension. Clinical Research 42(1): 5A, 1994

Inhaled nitric oxide in primary pulmonary hypertension. A safe and effective agent for predicting response to nifedipine. Journal of the American College of Cardiology 32(4): 1068-1073, 1998

Inhaled nitric oxide in primary pulmonary hypertension The Perfect pulmonary vasodilator. Circulation 92(8 SUPPL ): I241, 1995

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. European Respiratory Journal 12(2): 265-270, 1998

Acute vasodilator testing with oral high-dose calcium channel-blockers in primary pulmonary hypertension Comparison with nitric oxide. European Respiratory Journal 8(SUPPL 19): 195S, 1995

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(4): L723-L729, 2005

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, May 21, 2002

Comparison of acetylcholine and prostacyclin as screening agents for pulmonary vasodilator responsiveness in primary pulmonary hypertension. American Review of Respiratory Disease 135(4 PART 2): A350, 1987

Vasodilator response to inhaled nitric oxide is the most powerful predictor of survival in patients with pulmonary hypertension. Circulation 108(17 Supplement): IV-561, October 28, 2003

The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. American Heart Journal 150(4): 725-728, 2005

Stimulation of soluble guanylate cyclase attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide. FASEB Journal 18(4-5): Abst 688 14, 2004

Phosphodiesterase inhibition with dipyridamole augments and prolongs the pulmonary vasodilator response to inhaled nitric oxide in adults with chronic pulmonary hypertension. Circulation 98(17 SUPPL ): I614, Oct 27, 1998

Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatric Research 38(2): 198-204, 1995

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110(15): 2253-2259, 2004